SoLuTis Laser by Quantel Medical: Revolutionary Innovation for Glaucoma Treatment.
SoLuTis, the gem of Quantel Medical's laser technology, represents a groundbreaking advancement in glaucoma treatment since 1993. As a state-of-the-art Q-switched Selective Laser Trabeculoplasty (SLT) laser, SoLuTis has been designed to meet the specific needs of ophthalmologists and patients facing the challenges of glaucoma. This innovative solution is rooted in Quantel Medical's cutting-edge laser technology, which has consistently brought multiple innovations to glaucoma physicians worldwide since its inception in 1993.
SoLuTis stands out with its wavelength of 532 nm and its ability to adapt to Haag Streit-type slit lamps, providing unparalleled flexibility for eye health professionals. The use of SoLuTis offers an exceptional alternative to conventional treatments such as eye drops, surgery, and traditional laser procedures. By eliminating the need for invasive surgery and dependence on eye drops, SoLuTis paves the way for a more effective and comfortable treatment approach for glaucoma patients.
The uniqueness of SoLuTis lies in its advanced "photoregeneration" technology. Unlike traditional laser procedures such as Argon Laser Trabeculoplasty (ALT), Micropulse Laser Trabeculoplasty (MLT), Pattern Scan Laser Trabeculoplasty (PLT), etc., SoLuTis' SLT procedure is characterized by the absence of thermal effects. This innovative approach eliminates the destructive aspects associated with ALT, thus preserving the health of trabecular cells.
The specific treatment parameters of SoLuTis ensure maximum effectiveness while minimizing undesirable effects. With an extremely short pulse duration of 4 ns (0.000000004 sec) and a large spot size of 400 µm, SoLuTis offers exceptional precision in targeting pigmented cells. The optimal wavelength of 532 nm selectively targets melanin cells, while the fixed parameters avoid any visible or subvisible thermal effects.
SoLuTis stands as a safe and clinically proven therapy, backed by over ten years of clinical data. It is a non-invasive glaucoma treatment, increasingly used as a first-line option due to its effectiveness comparable to traditional laser treatments, yet repeatable over time. It serves as an alternative or complement to medical therapies, an adjunct to surgery, and conventional laser therapy.
One notable feature of SoLuTis is its user-friendly and adaptable design. With its laser fitting seamlessly into Quantel Medical slit lamps and Haag Streit-type slit lamps, SoLuTis integrates smoothly into the daily practice of ophthalmologists. Additionally, its compatibility with Quantel Medical's OPTIMIS II YAG laser offers an all-in-one platform for YAG and SLT lasers, further enhancing its versatility.
The portability of SoLuTis is a major asset, facilitating its transportation with a special carrying case. This feature makes the SoLuTis laser convenient and efficient, allowing healthcare professionals to safely transport it for off-site interventions. SoLuTis' effectiveness is further enhanced by its ability to easily combine with the OPTIMIS II YAG laser, providing a comprehensive solution for YAG and SLT treatments.
The compact and adaptable design of SoLuTis is another noteworthy aspect. Premium optical components ensure an even energy distribution, preserving the trabecular meshwork. The SoLuTis laser head can be effortlessly connected to most Haag Streit-type slit lamps, enabling users to perform SLT laser treatments with their diagnostic instrument. This makes SoLuTis not only clinically effective but also practical in the context of daily medical practice.
In terms of accessories, SoLuTis comes with a Gentle Footswitch for easy use and a practical carrying case to ensure safety and mobility during travels. These additional features contribute to making SoLuTis a comprehensive and user-friendly tool for eye health professionals.
SoLuTis embodies excellence in glaucoma treatment with its advanced laser technology, unique treatment parameters, and adaptable design. By providing a safe and effective alternative to conventional treatments, SoLuTis represents a significant advancement in glaucoma management, improving the quality of life for patients and facilitating the work of ophthalmologists.